Abstract:A substantial amount patients with cancer will develop bone metastases, with 70% of metastatic prostate and breast cancer patients harboring bone metastasis. Despite advancements in systemic therapies for advanced cancer, survival remains poor for those with bone metastases. The interaction between bone cells and the immune system contributes to a better understanding of the role that the immune system plays in the bone metastasis of cancer. The immune and bone systems share various molecules, including transcription factors, signaling molecules, and membrane receptors, which can stimulate the differentiation and activation of bone‐resorbing osteoclasts. The process of cancer metastasis to bone, which deregulates bone turnover and results in bone loss and skeletal-related events (SREs), is also controlled by primary cancer-related factors that modulate the intratumoral microenvironment as well as cellular immune process. The nuclear factor kappa B ligand (RANKL) and the receptor activator of nuclear factor kappa B (RANK) are key regulators of osteoclast development, bone metabolism, lymph node development, and T-cell/dendritic cell communication. RANKL is an osteoclastogenic cytokine that links the bone and the immune system. In this review, we highlight the role of RANKL and RANK in the immune microenvironment and bone metastases and review data on the role of the regulatory mechanism of immunity in bone metastases, which could be verified through clinical efficacy of RANKL inhibitors for cancer patients with bone metastases. With the discovery of the specific role of RANK signaling in osteoclastogenesis, the humanized monoclonal antibody against RANKL, such as denosumab, was available to prevent bone loss, SREs, and bone metastases, providing a unique opportunity to target RANKL/RANK as a future strategy to prevent bone metastases.

Development of Treatment in Metastatic Tumors Involving Bone

Research and Application of Target Therapy for Osteoporosis

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials

RANKL as a target for the treatment of osteoporosis

Targeting RANK/RANKL in the treatment of solid tumours and myeloma

Progress in pharmacological and clinical studies of denesumab,a new bone resorption inhibitorp

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies

Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis]

Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

Drug Therapy for Bone Metastasis of Malignant Tumor: Theory, Progress, and Potential.

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy

Discovery of the RANKL/RANK/OPG system

Cell biological mechanism of bone metastasis and cellular molecular targeted treatment

Targets in Systemic Molecular Targeted Therapies for Bone Metastases and Their Pharmacologic Agents

Structure-based Development of an Osteoprotegerin-Like Glycopeptide That Blocks RANKL/RANK Interactions and Reduces Ovariectomy-Induced Bone Loss in Mice.

Immune modulation with RANKL blockade through denosumab treatment in patients with cancer